Lab-Grown Cells Offer Hope for Curing Severe Type 1 Diabetes

A groundbreaking study has revealed that lab-grown insulin-producing cells could effectively cure diabetes type 1, offering renewed hope to patients who have long depended on limited donor organ supplies. While the findings are preliminary, researchers describe them as promising, indicating this development could potentially make treatment accessible to a significantly larger number of people living with this autoimmune condition, according to NOS.

The Challenge of Type 1 Diabetes

Unlike type 2 diabetes, predominantly associated with aging and lifestyle factors, diabetes type 1 arises when the immune system attacks the pancreas’s insulin-producing cells. Approximately 120,000 people in the Netherlands live with type 1 diabetes. While most manage their condition with medication, they remain at increased risk of complications affecting their eyes, kidneys, heart, and blood vessels.

For a small subset of patients with particularly severe cases, standard medications are insufficient. Until now, their only options were full pancreas transplants or islet cell transplants, which involve transplanting clusters of insulin-producing cells taken from deceased donors. These procedures can enable patients to achieve complete remission or, at the very least, maintain stable blood sugar levels with reduced medication reliance. However, the scarcity of suitable donor organs has limited these treatments to only a select few.

A Potential Breakthrough Solution

The new study introduces a groundbreaking approach. Scientists have successfully developed insulin-producing islet cells in a laboratory using pluripotent stem cells—undifferentiated cells capable of evolving into any cell type in the body. Preliminary results show that most participants with severe diabetes type 1 were free of the disease one year after receiving infusions of these lab-grown cells.

“The real breakthrough is that islets made from stem cells in a laboratory can functionally cure diabetes,” explained Eelco de Koning, a physician and professor of diabetology at Leiden University Medical Center. “This demonstrates that, in the future, an unlimited supply of islets could be available for treatment.”

Ongoing Research and Future Potential

While the findings are encouraging, further research is essential before this method can be integrated into standard medical care. Supported by the Stichting Diabetes Onderzoek Nederland, a new research center named Cure One is set to open in Leiden this November. The center will consolidate research on stem cell therapies and the interplay between the immune system and diabetes. It is expected to bolster both Leiden University Medical Center (LUMC) and the Leiden Bioscience Park as European hubs for diabetes treatment innovation.

One of Cure One’s main goals is to make this therapy accessible to all type 1 diabetes patients. However, current limitations remain. Both recipients of donor-derived islets and those receiving lab-grown cells must take long-term immune-suppressing medication to prevent rejection. While this prevents the immune system from attacking the transplanted cells, it leaves patients vulnerable to infections and other side effects, raising concerns about whether the treatment is beneficial for patients with less complex cases.

Addressing the Immune System Complication

“The challenge is to adapt the stem cells and the immune system so the immune system doesn’t attack the new islets,” De Koning shared. Another potential approach involves deriving stem cells directly from type 1 diabetes patients and using them to grow personalized islets.

“With expertise concentrated in Cure One, we will explore every avenue to ensure another breakthrough is just around the corner,” De Koning added.

This study marks an important step forward in diabetes research, offering hope that, one day, treatments for type 1 diabetes could be more effective, accessible, and personalized, changing the lives of millions worldwide.